التفاصيل البيبلوغرافية
| العنوان: |
Estimating the cost‐effectiveness of intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in England. |
| المؤلفون: |
Elliott, Rachel A., Rogers, Gabriel, Evans, Mark L., Neupane, Sankalpa, Rayman, Gerry, Lumley, Sarah, Cranston, Iain, Narendran, Parth, Sutton, Christopher J., Taxiarchi, Vicky P., Burns, Matthew, Thabit, Hood, Wilmot, Emma G., Leelarathna, Lalantha |
| المصدر: |
Diabetic Medicine; Mar2024, Vol. 41 Issue 3, p1-13, 13p |
| مصطلحات موضوعية: |
GLYCOSYLATED hemoglobin, CONFIDENCE intervals, BLOOD sugar monitoring, TYPE 1 diabetes, MEDICAL care costs, COST control, HEALTH status indicators, RANDOMIZED controlled trials, COST effectiveness, QUESTIONNAIRES, DESCRIPTIVE statistics, RESEARCH funding, STATISTICAL sampling, CONTINUOUS glucose monitoring, QUALITY-adjusted life years, ECONOMICS, ADULTS |
| مصطلحات جغرافية: |
ENGLAND |
| مستخلص: |
Objective: We previously showed that intermittently scanned continuous glucose monitoring (isCGM) reduces HbA1c at 24 weeks compared with self‐monitoring of blood glucose with finger pricking (SMBG) in adults with type 1 diabetes and high HbA1c levels (58–97 mmol/mol [7.5%–11%]). We aim to assess the economic impact of isCGM compared with SMBG. Methods: Participant‐level baseline and follow‐up health status (EQ‐5D‐5L) and within‐trial healthcare resource‐use data were collected. Quality‐adjusted life‐years (QALYs) were derived at 24 weeks, adjusting for baseline EQ‐5D‐5L. Participant‐level costs were generated. Using the IQVIA CORE Diabetes Model, economic analysis was performed from the National Health Service perspective over a lifetime horizon, discounted at 3.5%. Results: Within‐trial EQ‐5D‐5L showed non‐significant adjusted incremental QALY gain of 0.006 (95% CI: −0.007 to 0.019) for isCGM compared with SMBG and an adjusted cost increase of £548 (95% CI: 381–714) per participant. The lifetime projected incremental cost (95% CI) of isCGM was £1954 (−5108 to 8904) with an incremental QALY (95% CI) gain of 0.436 (0.195–0.652) resulting in an incremental cost‐per‐QALY of £4477. In all subgroups, isCGM had an incremental cost‐per‐QALY better than £20,000 compared with SMBG; for people with baseline HbA1c >75 mmol/mol (9.0%), it was cost‐saving. Sensitivity analysis suggested that isCGM remains cost‐effective if its effectiveness lasts for at least 7 years. Conclusion: While isCGM is associated with increased short‐term costs, compared with SMBG, its benefits in lowering HbA1c will lead to sufficient long‐term health‐gains and cost‐savings to justify costs, so long as the effect lasts into the medium term. [ABSTRACT FROM AUTHOR] |
|
Copyright of Diabetic Medicine is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
